Related by context. All words. (Click for frequent words.) 60 Thromboembolic 59 RECIST Response Evaluation Criteria 59 Nonalcoholic Fatty Liver Disease 59 prospective multicenter study 59 baseline LDH 59 Patient Registry 59 Patient Outcomes 59 Acute Decompensated Heart Failure 59 Cancer Patients Treated 58 Patients Receiving 58 Randomized Study 58 NSABP B 58 liver transplant recipients 58 Hematologic 58 Microalbuminuria 58 serum lipid levels 57 Adenomas 57 Clinical Practice Guideline 57 Oral Fingolimod 57 epoetin alpha 57 seropositivity 57 relapsed MM 57 Intervention Trial 57 Ascites 57 Systemic Lupus Erythematosus SLE 57 Reduces Mortality 57 Solid Tumors 57 Systemic Sclerosis 57 Severe Sepsis 57 Inflammatory Markers 57 Improves Outcomes 57 Solid Tumors criteria 57 Erythropoiesis Stimulating Agents 57 Complete Remission 57 Arch Intern Med 57 Stent Restenosis 57 Stent Thrombosis 57 Multicenter Study 57 Subtypes 57 Pulmonary Arterial Hypertension 57 Iron Overload 56 Tyrosine Kinase Inhibitors 56 Treatment Outcome 56 Neoplasia 56 Gastric Cancer 56 Cardiotoxicity 56 Lupus Nephritis 56 Renal Cancer 56 Infarct 56 Bacteremia 56 Prolongs Survival 56 CHAMPION PCI 56 Tumor Response 56 Diagnostic Criteria 56 Pivotal Trial 56 Society CTOS 56 BR.# 56 RECORD1 56 Histological 56 Coronary Artery Bypass Graft 56 Risk Stratification 56 Malignant Lymphoma 56 Initiates Clinical Trial 56 #:#-# [033] 56 Echocardiographic 56 ABCSG 56 Thrombotic 56 Hematological 55 J Clin Endocrinol Metab 55 HIV HCV coinfected 55 Peripheral Arterial 55 metastatic gastric 55 BCIRG 55 AST ALT 55 Clinical Practice Guidelines 55 Acute Ischemic Stroke 55 HSCT 55 clinico pathological 55 Quality Indicators 55 Clinical Outcome 55 Acute Myocardial Infarction 55 Chronic Heart Failure 55 ASCO GI 55 pT2 55 Pharmacodynamic 55 Emerging Therapies 55 histological subtype 55 Patients Treated With 55 Neuropathic Pain 55 Pharmacodynamics 55 serum lactate 55 Kidney Disease Outcomes 55 LHON 55 Skin sterol 55 Insulin Therapy 55 Coronary artery bypass grafting 55 Adjuvant Therapy 55 Bipolar Disorders 55 Hormone Refractory Prostate Cancer 55 SSc patients 55 multicentre prospective 55 Therapeutic Advances 55 Prospective Randomized 55 Solid Tumours 55 Carotid Endarterectomy 55 Cardiometabolic 55 Renal Cell Carcinoma RCC 55 Juvenile Idiopathic Arthritis 54 Hemodialysis Patients 54 recurrent glioblastoma multiforme 54 multicenter randomized controlled 54 Hepatocellular Carcinoma 54 antiretroviral naïve 54 observational cohort study 54 Erythropoietic 54 aminotransferase 54 metastatic malignant 54 Metabolic Endocrinology 54 Progenitor Cells 54 Clinical Evaluation 54 Oropharyngeal 54 Allogeneic 54 Yondelis ® 54 Antiplatelet 54 patientswith 54 Biphasic 54 Transcatheter 54 Acute Heart Failure 54 urolithiasis 54 QT Prolongation 54 null responder 54 Epoetin Alfa 54 Septic Shock 54 prospective observational cohort 54 Delayed Graft Function 54 Maven Semantic 54 Outcome Measures 54 Cardiovascular Outcomes 54 Hyperlipidemia 54 Prostate Cancer Risk 54 Angiographic 54 surgically resected 54 ANTEGREN 54 ST Segment Elevation 54 Placebo Controlled Trial 54 SSc 54 atypical Hemolytic Uremic Syndrome 54 Index CDAI 54 EFNS 54 Treat Anemia 54 J Nutr 54 Acute Renal Failure 54 Guideline Update 54 Cutaneous T 54 #:#-# [031] 54 clinicopathological 54 osteoporotic vertebral fractures 54 Diabetic Foot Ulcer 54 Comorbidities 54 retrospectively analyzed 54 Successfully Treated 54 Multiple Myeloma Patients 54 ICAAC IDSA 54 papillary renal cell carcinoma 54 Systolic Blood Pressure 54 foveal thickness 54 Myelodysplastic Syndromes 54 Non Alcoholic Fatty 54 Prognostic 54 HoFH 54 Myelodysplastic Syndrome 54 transrectal ultrasound guided 54 Arteriosclerosis 54 Main Outcome Measure 54 Phase Ib II 54 nonmetastatic 54 Arch Neurol 54 Phase III Clinical Trial 53 Cognitive Impairment 53 Etiology 53 Doxil ® 53 Score TOS 53 Heart Transplant Recipients 53 Shows Promise Against 53 haematologic 53 See CLINICAL PHARMACOLOGY 53 allogeneic bone marrow 53 ImmuKnow assay 53 retrospective observational study 53 clevidipine 53 Randomized Controlled Trials 53 Tumor Microenvironment 53 lymphoid malignancies 53 KDOQI 53 multivariate Cox 53 Laryngeal Cancer 53 Randomized Evaluation 53 Tumor Markers 53 Proliferative 53 Ischemic Stroke 53 Connective Tissue Oncology 53 COPERNICUS 53 Carotid Artery Stenting 53 Interventional Procedures 53 NSQIP 53 ACR# ACR# 53 CALGB # [002] 53 Adverse Event 53 essential thrombocythemia ET 53 allogeneic hematopoietic stem cell 53 Adult Stem Cell Therapy 53 Arterial Hypertension 53 Novel Inhibitor 53 Cytogenetic 53 Demonstrates Sustained 53 AA Amyloidosis 53 Renal Artery 53 Surgical Treatment 53 Inflammatory Disease 53 genitourinary cancers 53 ST Elevation Myocardial 53 Shows Efficacy 53 prospective observational 53 Clinical Trial Results 53 Delcath Phase III 53 Prostate Cancer Screening 53 Current Controlled Trials 53 Val HeFT 53 Stage IIIA 53 cTnI 53 Main Outcome Measures 53 CALGB 53 Late Breaker 53 longitudinal cohort study 53 Cholinesterase Inhibitors 53 Severe Asthma 53 metastatic neuroendocrine tumors 53 Estrogen Receptor 53 Continence Society 53 Multicenter 53 Myocardial Ischemia 53 N Engl J 53 Fondaparinux 53 Evoltra ® 53 Lp PLA 2 53 Predict Risk 53 Combination REOLYSIN R 53 Demonstrate Significant 53 Myocardial Infarction 53 Kidney Transplant Patients 53 Thromboembolism 53 Am J Epidemiol 53 Warfarin Coumadin 53 Arrhythmias 53 Prognostic Value 53 Aryplase 53 number NCT# ClinicalTrials.gov 53 allogeneic hematopoietic cell 52 SABCS 52 Trandolapril 52 Oesophageal 52 Malignancies 52 Oxygen Saturation 52 observational cohort 52 Long Term Efficacy 52 Acute Stroke 52 J Urol 52 Neoplasms 52 Therapeutic Intervention 52 Thrombolysis 52 Histologic 52 Vertebral Fractures 52 Venous Thromboembolism 52 tissue oxygenation 52 Slow Progression 52 Hepatic 52 hyperphenylalaninemia HPA due 52 Quality Initiative KDOQI 52 prospective multicentre 52 ZACTIMA 52 plerixafor 52 Hospital Clínic 52 Soft Tissue Sarcoma 52 Hsp# Inhibitor 52 Aneurysm Repair 52 Parathyroid 52 Mantle Cell Lymphoma 52 ISPOR 52 pain palliation 52 huN# DM1 52 ACUITY trial 52 Investigational Drug 52 Heart Failure Patients 52 Pharmacokinetic parameters 52 Response Evaluation Criteria 52 ECCO ESMO 52 Myelodysplastic Syndrome MDS 52 Carotid Stenting 52 Islet Transplant 52 Vitrectomy 52 Clinical Relevance 52 epoetin beta 52 Edge STudy 52 Cognitive Function 52 Catena ® 52 Metabolic Disorders 52 Outpatient Setting 52 ATIR 52 Prospective Multicenter 52 ICAEL 52 Phase 2b Clinical Trial 52 Plaque Psoriasis 52 Levels Linked 52 NAVISTAR R 52 iPTH 52 Hematopoietic 52 Controlled Trial 52 Pivotal Clinical Trial 52 HYVET 52 Basilea Toctino R 52 Group RTOG 52 Renal Function 52 Heavy menstrual bleeding 52 Oncologic 52 unstable angina pectoris 52 Breast Carcinoma 52 Immune Mediated 52 Advanced Melanoma 52 Vaccine Immunology 52 relapsing multiple sclerosis 52 USpella 52 J Am Coll 52 leiomyomas 52 Ankylosing Spondylitis 52 Hypertriglyceridemia 52 Erythropoiesis Stimulating Agents ESAs 52 Eye Diseases 52 ASH Annual Meeting 52 BPS IC 52 Cimzia TM 52 INSPIRE Trial Phase III 52 Insulin Resistance 52 μg L 52 PEG IFN 52 Mammography Screening 52 Recurrent Chest Wall 52 ARCOXIA 52 League Against Rheumatism 52 Non inferiority 52 Advanced Renal Cell 52 Non Responders 52 IPAH 52 Hospitalized Patients 52 Sevelamer 52 Infarction 52 Comorbidity 52 IIIb 52 MassGeneral Institute 52 gm dL 52 Acute Coronary 52 Cost Effectiveness 52 Sleep Disturbances 52 HER2 Positive 52 multiple myeloma MM 51 Prostatic 51 clinically evaluable 51 #:#-# [023] 51 Decompensated 51 Guidelines Issued 51 Recurrent Breast Cancer 51 Germ Cell 51 Clinical Guideline 51 Histopathological 51 Carotid Revascularization Endarterectomy vs. 51 oral FTY# 51 Naive Patients 51 Newly Diagnosed Patients 51 Phase III Trial 51 demonstrated antitumor activity 51 Cellular Immunotherapy 51 Unstable Angina 51 Paroxysmal Nocturnal Hemoglobinuria PNH 51 SORT OUT III 51 Transplant Rejection 51 Rigshospitalet Copenhagen Denmark 51 Triapine R 51 Adiposity 51 mITT population 51 #OHD 51 thetreatment 51 Myocardial 51 Gynecologic Oncology Group 51 LUMINATE 51 Successfully Treats 51 evaluating mipomersen 51 Patients Treated 51 J Nucl Med 51 Ocular Inflammation 51 phase IIIb 51 Initiates Phase III 51 Marrow Transplant 51 Node Negative 51 Ranolazine 51 Cloretazine 51 hemodynamic variables 51 Postmenopausal 51 Valvular 51 Treatment Approaches 51 Phase Ib Clinical Trial 51 Bone Metastases 51 Left Ventricular 51 % CI #.#-#.# [008] 51 T2DM 51 thymoma 51 Clinicaltrials.gov 51 #-# Full Text 51 Phase Ib study 51 Neurosurgical Products 51 Patients Undergoing 51 Surgical Procedures 51 histologically confirmed 51 Eculizumab 51 Interventional Radiological Society 51 fosbretabulin 51 Antisoma AS# 51 Differential Diagnosis 51 Myocardial Perfusion 51 Multicentre 51 Granted Orphan Drug 51 Vascular Imaging 51 Clinical Significance 51 angiographically 51 sirolimus eluting stents 51 Cervical Cytology 51 Lowers Risk 51 myocardial infarct size 51 Uterine Fibroid 51 Stenosis 51 Combo Therapy 51 Mouse Models 51 Investigational Treatment 51 Rheumatoid Arthritis Patients 51 Islet Cell 51 Renal Failure 51 Intensive Care Medicine 51 Chronic HCV 51 Female Urology 51 Gonal f 51 Juvenile Idiopathic Arthritis JIA 51 ACR# responses 51 Venous Thrombosis 51 Preclinical Study 51 Therapeutic Targets 51 serum LDL cholesterol 51 Significantly Improves 51 Interstitial Cystitis 51 Cardiac Marker 51 HepaSphere 51 Refractory Angina 51 prospectively evaluated 51 Drug Shows Promise 51 Hematopoietic Stem Cell Transplantation 51 Acute MI 51 Colorectal 51 Bone Marrow Transplants 51 Acute Liver Failure 51 oocytes retrieved 51 ARIXTRA 51 Cloretazine R 51 ECCMID 51 Conjugate 51 Gets FDA Clearance 51 AIR2 Trial 51 phase IIb study 51 Phase IIIb study 51 ACOMPLIA R 51 EORTC 51 prostate cancer CaP 51 Pregnancy Outcomes 51 IDDM 51 Certican 50 Coronary Intervention 50 Lancisi Heart Institute 50 Ospedali Riuniti 50 Psychiatric Disorders 50 Allogeneic Stem 50 Sentinel Lymph Node 50 Premature Infants 50 restenotic lesions 50 Basal Cell 50 Hospital Universitario 50 Inflammatory Bowel Diseases 50 cutaneous melanoma 50 Excretion 50 Lung Transplantation 50 CLARITY study 50 B streptococcal 50 Omacetaxine 50 Protein Expression 50 Motility 50 Angiox R 50 Diabetology 50 prospective nonrandomized 50 Quantitation 50 Receives Orphan Drug Designation 50 Poster Discussion 50 ABRF 50 Cardiovascular Disease Risk 50 Tumor Cell 50 Cervical Cancer Screening 50 MR Spectroscopy 50 peripartum 50 efficacy evaluable 50 EACTS 50 Mortality Risk 50 ASCO GU 50 Breast Ultrasound 50 Anthropometric 50 Paroxysmal Nocturnal Hemoglobinuria 50 Embryology ESHRE 50 Anticoagulation 50 miRview meso 50 Minimally Invasive Treatment 50 satraplatin Phase 50 Stenting Trial CREST 50 Sociodemographic 50 familial amyloidotic polyneuropathy FAP 50 Acute Coronary Syndromes 50 Cervical Cancer Detection 50 pediatric acute lymphoblastic 50 #:# -# [003] 50 preeclamptic 50 AACR San Antonio 50 atherothrombotic disease 50 Holter Monitoring 50 ECTRIMS 50 Intravascular 50 biostatistical analysis 50 Remote Patient Monitoring 50 Pharmacologic 50 Urology Devices 50 Genes Identified 50 SIADH 50 precancerous cervical 50 Multiple Ascending Dose 50 NICE SUGAR 50 Brief Psychiatric 50 urodynamic parameters 50 Improve Survival 50 carotid artery stenting CAS 50 Bronchial Asthma 50 Mitotic 50 Multiethnic Study 50 CABG Surgery 50 ELBW infants 50 #:#-# [035] 50 Thrombophilia 50 Electroencephalography 50 Liraglutide Effect 50 Primary endpoints 50 Ocrelizumab 50 Cardiorespiratory fitness 50 Pulmonary Hypertension 50 ACC AHA 50 Dialysis Outcomes 50 GW# [003] 50 Novel Treatments 50 kidney urologic 50 Postdoctoral Position 50 colorectal cancer CRC 50 Advanced Heart Failure 50 HCV Protease Inhibitor 50 Bazedoxifene 50 Therapeutic Approaches 50 Cimzia ® certolizumab pegol 50 Coronary Revascularization 50 Practice Guideline 50 stage IIIB 50 Functional Outcomes 50 PreDx DRS 50 neoadjuvant treatment 50 urinary iodine 50 hMG 50 Hepatocellular Carcinoma HCC 50 localized prostate 50 Low Incidence 50 Novel Therapeutics 50 Febrile Neutropenia 50 uricase 50 MEND CABG II 50 Hematologic Oncology 50 Multicenter AIDS 50 atherothrombosis 50 Valvular Heart Disease 50 Coagulation 50 benign gynecological 50 Chronic Hepatitis B 50 Oncological 50 GG genotype 50 β blockers 50 Autoimmune Diseases 50 Benign Prostatic Hyperplasia BPH 50 Antibody Therapy 50 PCWP 50 Localized Prostate Cancer 50 Secondary efficacy endpoints 50 Cellular Therapy 50 depsipeptide 50 Test Detects 50 LSE ASM 50 Clinical Efficacy 49 Uterine Fibroid Embolization 49 thalidomide Thalomid 49 Cryoablation 49 Masimo noninvasive 49 Autoantibodies 49 Vasogen Celacade 49 Percutaneous Coronary Intervention 49 OvaRex MAb 49 polycythemia vera essential thrombocythemia 49 J Pediatr 49 Albuminuria 49 Lupus Drug 49 Wound Closure 49 PROactive Study 49 cerebral oximetry 49 genomic biomarker 49 alpha antagonist 49 TG MV 49 recurrent miscarriage 49 Cerebrospinal Fluid 49 Poster Presentation 49 euthyroid 49 Prospective Cohort Study 49 IN VITRO 49 mycophenolate mofetil MMF 49 Targeted Therapies 49 IMiDs ® compound 49 acute humoral rejection 49 ALS Functional 49 Environ Health Perspect 49 colorectal carcinoma 49 cisplatin gemcitabine 49 LungSign TM 49 Signaling Pathway 49 PEGylated interferon beta 1a 49 Announces Poster Presentations 49 Percutaneous Coronary Interventions 49 Platinol ® cisplatin 49 Functional Assessment 49 ImmuKnow R 49 Nutritional Status 49 Diabetes Hypertension 49 Aggressive Reduction 49 Atrial Flutter 49 R vitespen 49 PROSTASCINT R 49 Chronic Obstructive Pulmonary 49 recurrent glioma 49 antenatal corticosteroids 49 Distinguished Hospitals 49 prostate carcinoma 49 Hematologic Malignancies 49 System USRDS 49 Angiogenic 49 adiponectin concentrations 49 Overactive Bladder 49 hypereosinophilic syndrome 49 Velcade bortezomib 49 Bladder Cancer 49 Gene Linked 49 Stress Incontinence 49 BCR ABL inhibitor 49 Lesion 49 prospectively defined 49 Biological Therapy 49 COPAXONE R 49 National Oncologic PET 49 bronchopulmonary 49 Meta Analysis 49 receptor tyrosine kinase inhibitor 49 nd Annual Meeting 49 #:# -# [005] 49 PPCM 49 Febuxostat 49 Group ECOG 49 Molecular Diagnostic Test 49 Orally Active 49 NIDDM 49 Non Invasive Treatment 49 Treatment Reduces 49 Cognitive Problems 49 adjuvant systemic 49 Gastrointestinal Disorders 49 Electrophysiology Mapping 49 lexidronam injection 49 SWOG 49 buccal spray 49 Initiates Phase 2b 49 Amrubicin 49 ENDEAVOR IV 49 Phenotype 49 metaanalysis 49 Appropriateness Criteria 49 Digital Mammographic Imaging 49 Therapeutics TCT scientific 49 Abstract P# [002] 49 Phase Ib clinical 49 ON #.Na 49 Meta analyzes 49 YONDELIS R 49 Bone Metabolism 49 Stent Placement 49 Spine Patient Outcomes 49 Selective Cardiac Myosin Activator 49 Lysis 49 Gastrointestinal Cancers Symposium 49 NKI AVL 49 ACCF AHA 49 Bucindolol 49 ATACAND 49 Randomized Trials 49 GH deficiency 49 onset diabetes mellitus 49 IL# PE#QQR 49 #:# -# [006] 49 Depressive Symptoms 49 Stable Angina 49 Genes Involved 49 Musculoskeletal Disorders 49 diabetic polyneuropathy 49 Pressure Monitoring 49 NeoRecormon 49 Anticancer Drug 49 Epitopes 49 Inflammatory Arthritis 49 vitro cytotoxicity 49 NCIC CTG 49 Alitretinoin 49 PDE# inhibitors 49 underwent CABG 49 Nebulized Formoterol 49 Reimbursement Issues 49 Proves Effective 49 desvenlafaxine succinate 49 HIV seropositive 49 Medizinische 49 Serious Infections 49 Breast Cancer Survival 49 Capacity FVC 49 pancreatic islet cell 49 Platelet Aggregation 49 retrospective cohort study 49 VerifyNow 49 Heart Rate Variability 49 Liver Disease 49 Bioavailability 49 Antiviral Activity 49 AlloMap testing 49 Physiologic 49 Gonadotropin 49 Heterogeneity 49 autologous hematopoietic stem cell 49 CyberKnife Radiosurgery 49 International Myeloma Workshop 49 Genes Discovered 49 Cardiac Rhythm 49 HIV Cohort Study 49 HDL Selective Delipidation 49 Kidney Transplants 49 Pharmaceuticals Initiates 49 Vascular Annual Meeting 49 Myeloperoxidase 49 Left Atrial 49 multicenter phase 49 dimeglumine 49 preclinical efficacy 49 Hemostasis 49 Symptom Checklist 49 Spinal Manipulation 49 abnormal cytology 49 Neuroprotection 49 corticosteroid induced 49 Anaemia 49 Susceptibility Testing 49 Breast Tumor 49 Gynaecological Oncology 49 ISTODAX ® 49 Polymorphisms 49 aged ≥ 49 Patient Treated 48 gefitinib Iressa 48 sunitinib Sutent 48 Polymorphism 48 Minimally Invasive Procedure 48 Psychotic Disorders 48 Crit Care Med 48 bone marrow reticulin deposition 48 Phase III psoriasis 48 Proc Am Soc 48 Optical Coherence Tomography 48 Nonalcoholic Steatohepatitis 48 Eylau Centre 48 Cancer Incidence 48 Disease Modifying 48 Severity Index 48 Phase III HEAT 48 Bendamustine 48 BALF 48 GRNCM1 48 nephrolithiasis 48 genes differentially expressed 48 Genitourinary Cancers Symposium 48 ANSI AAMI 48 Hypertension ESH 48 Systematic Review 48 pharmacokinetic characteristics 48 Homeostasis 48 radiation dosimetry 48 Sleep Disordered Breathing 48 fasting plasma 48 Endocrine Society #st 48 HBeAg negative patients 48 CRLX# 48 pharmacokinetic PK 48 multicentre study 48 somatostatin analog 48 perinatal outcomes 48 Hematology Meeting 48 Bosutinib 48 R darbepoetin alfa 48 hematopoietic cell 48 CP CPPS 48 Platelet Function 48 Initiative K DOQI 48 Childhood Asthma 48 SF #v# 48 Limb Salvage 48 antiangiogenic agent 48 Metabolic Disease 48 Cardiovascular Risk Factors 48 Pancreatic 48 Resource Utilization 48 pancreatic adenocarcinoma 48 Signaling Pathways 48 neuropathologic 48 Breast Cancer Treatment 48 Anxiety Depression 48 Sleep Disturbance 48 Nicotine Vaccine 48 Phase 2b Trial 48 molar pregnancy 48 congenital toxoplasmosis 48 haematologic malignancies 48 Fibromyalgia Syndrome 48 Congenital Heart Disease 48 somatosensory evoked potentials 48 Tracleer ® bosentan 48 Clin J 48 LDH lactate dehydrogenase 48 Chronic Obstructive Lung 48 Telatinib 48 Therapeutic Antibody 48 Selective Cardiac Myosin 48 choriocarcinoma 48 Axillary 48 laparoscopic radical nephrectomy 48 CIBMTR 48 Endovascular System 48 Beta Amyloid 48 antithrombotic therapy 48 Tumor Registry 48 Quinamed 48 Services #:#-#,# Abstract 48 Phase #b/#a clinical 48 arterial hypertension 48 Lupus Erythematosus 48 TAXUS V 48 Therapy Shows Promise 48 murine model 48 NABTT 48 Biological Effects 48 Contrast Agents 48 Antitumor 48 Vascular Disease 48 multicentric 48 Dysplasia 48 Post Operative 48 abstracts summarizing 48 Kantonsspital 48 Mitral Valve Repair 48 Confidence Intervals 48 Eur J 48 #:#-#,# CrossRef Medline [002] 48 EULAR Annual 48 decitabine 48 polyarticular 48 Myelodysplastic Syndromes MDS 48 Radiation Dose 48 Gynecological Cancer 48 Dry Powder Inhalers 48 GELA 48 EMR Adoption 48 urological cancers 48 FDA Approves Drug 48 INTRABEAM ® 48 Inflammatory Diseases 48 Dyspnea 48 Tissue Engineered 48 Onko Sure TM 48 Initiates Enrollment 48 Podium Presentation 48 conducted retrospective cohort 48 NMP# BladderChek 48 Orofacial 48 Hospital Universitari 48 eribulin mesylate 48 Psychiatric Services #:#-#,# 48 MELAS 48 Urology Gynecology 48 Scale EDSS score 48 Antithrombotic 48 Cystectomy 48 Genes Linked 48 Supplementary Appendix 48 Circulatory Support 48 Irbesartan 48 Assessment Questionnaire 48 Tramiprosate ALZHEMED TM 48 EADV 48 NTIOL 48 randomized Phase 2b 48 Receives Positive Opinion 48 RAPAFLO R 48 CAPRA 48 HDAC Inhibitor 48 Randomized Clinical Trials 48 multicenter prospective 48 nonpregnant women 48 Inhaled Nitric Oxide 48 Fine Needle Aspiration 48 CRVO 48 Osteoporosis Screening 48 ERA EDTA 48 ESCRS 48 FRDA patients 48 iSBTc 48 Macrophage 48 CLINICAL STUDIES 48 sustained virological response 48 coexisting illnesses 48 microplasmin Phase III 48 Gynecologic 48 Cognitive Dysfunction 48 Antidepressant Treatment 48 metabolite concentrations 48 Gentium Announces 48 Systemic Therapy 48 DNA Microarray 48 MAPT 48 Radiofrequency Ablation 47 Helps Diagnose 47 Zenvia Phase III 47 evaluating tivozanib 47 briakinumab 47 Dr. Michelle Berrey 47 ASGCT 47 Urocortin 2 47 EASE Program 47 Oximeter 47 Technosphere ® 47 controlled ovarian hyperstimulation 47 Chicago Multidisciplinary Symposium 47 GISSI 47 Int J 47 EORTC NCI AACR 47 Cholesterol Levels SPARCL 47 induced hepatotoxicity 47 Prenatal Diagnosis 47 Phase 2a Clinical Trial 47 Respiratory Symptoms 47 Multicenter Phase 47 PENTASA 47 urine dipstick 47 TIMP 1 47 Kahalalide F 47 GORE TAG Device 47 Allergology 47 Predictive Toxicology 47 Dr. Kandzari 47 Testis 47 Hepatobiliary 47 Disease Severity 47 myocardial infarction ventricular fibrillation 47 WOMAC scores 47 CONBRIZA 47 Enhanced External Counterpulsation 47 Chemotherapy Improves 47 Free Full Text